Duodenal ulcers are part of a broader disease state categorized as peptic ulcer diseaseWhile most duodenal ulcers present with dyspepsia as the primary associated symptom, the presentation can range in severity levels, including gastrointestinal bleeding, gastric outlet obstruction, perforation, or fistula development. Proton-pump inhibitors (PPIs) have been very efficacious for the management of ulcer. Omeprazole degrades very rapidly in aqueous solutions at low pH values. Omeprazole degradation is acid-catalysed; with an increase in the pH values, the rate of degradation decreases. So, delivery of therapeutic agent into the intestinal region could be accomplished by the application of an enteric coating on a solid dosage form. So, the aim of this study is formulation of delayed release Omeprazole for treatment of Duodenal ulcers. The formulation & evaluation of formulated drug was done according to standard procedures. Particle size analysis result shows that 90 % of particles were in range of 36.031 to 37.592 µm. which showed uniformity of particle size. Moisture content was found to be 0.3%.Weight variation data of core tablets formulated using both direct compression and wet granulation indicated that they were in range of official standards and no significant difference between individual weights of tablets from the average value. Formulation F008 formulated by 4mg of PVP K 30 per tablet along with IPA shows highest drug release among other batches core tablet by wet granulation method. Thus Formulation F008 posses delayed release property so can be used to cure duodenal ulcers. Keywords: Duodenal ulcers, Omeprazole, Delayed release, Tablet